hVIVO plc (LON:HVO) (formerly Open Orphan plc), a rapidly growing specialist contract research organisation (CRO) and world leader in testing infectious and respiratory disease products using human challenge clinical trials, has announced
Venn Life Sciences, the consultancy services division of Hvivo, has secured a two-year contract with a pharmaceutical client worth €3.2m. A consultancy team based in the Netherlands will provide drug
The NHS has faced unprecedented challenges in recent years, particularly during the Covid-19 pandemic, leading to strain on services and delays in treatment. Efforts are being made to address this
Several vaccine companies say they are expecting breakthroughs as early as this year as they pursue new ways to protect people against SARS-CoV-2, the virus that causes COVID-19. The Food and
Poolbeg Pharma, a biopharmaceutical company that specialises in infectious diseases, has filed a patent for one of its treatments to be used in cancer treatments. The treatment, called POLB 001,
Avingtrans PLC (LON:AVG), which designs, manufactures and supplies critical components, modules, systems and associated services to the energy, medical and industrial sectors, has announced that shareholders of Magnetica have approved an increase
N4 Pharma Plc (LON:N4P), the specialist pharmaceutical company developing Nuvec®, a novel delivery system for cancer treatments and vaccines, has provided an update on its ongoing Australian Research Council grant
hVIVO plc (LON:HVO) (formerly Open Orphan plc), a rapidly growing specialist contract research organisation (CRO) and world leader in testing infectious and respiratory disease products using human challenge clinical trials, has announced
The days are short, cold, and wet. Festive overindulgence has left you feeling sluggish. Your New Year’s resolutions have been lost in the fog of January. There are many reasons
© 2022 – DirectorsTalk. All rights reserved. Reproduction in whole or in part, in any form or medium without express written permission is prohibited.
